Confluence University Osara Receives NUC’s Approval for Medicine, Law, and Four Other Courses

The Confluence University of Science and Technology (CUSTECH), Osara, located in Kogi State, has officially received approval from the National Universities Commission (NUC) to offer Medicine and Surgery, Law, and four additional programs. This milestone solidifies the institution’s standing as a state-run university committed to expanding academic excellence.

The newly approved programs include:

  • Bachelor of Medicine and Surgery (MBBS)
  • Doctor of Physiotherapy (DPT)
  • Bachelor of Radiography (B.Rad)
  • Bachelor of Agriculture (B.Agric)
  • Bachelor of Agricultural Engineering (B.Eng)
  • Bachelor of Laws (LL.B)

The approvals were granted by the NUC following a thorough resource verification process. In a letter dated September 5, 2024, the Acting Executive Secretary of the NUC, Chris J. Maiyaki, communicated this decision to the university’s Vice-Chancellor. The letter emphasized that these courses would be implemented at the university’s main campus starting from the 2024/2025 academic session.

The assessment was based on the human and material resources available at CUSTECH, and the NUC concluded that the university is fully equipped to run the programs successfully. However, the approval applies strictly to full-time programs, with no provision for part-time studies at this time. Should the university wish to initiate part-time options, they would need to submit a separate request for NUC’s consideration.

The Confluence University of Science and Technology was established in 2020 during the administration of former Governor Yahaya Bello. This new approval by the NUC signals a significant step forward in the university’s development and its ability to offer high-quality education in fields critical to the state’s and nation’s growth.

Stay tuned to OhonoTV for more updates on CUSTECH’s progress and the latest education news in Nigeria.

Our WhatsApp Group OhonoTV WhatsApp Group

LEAVE A REPLY

Please enter your comment!
Please enter your name here

The reCAPTCHA verification period has expired. Please reload the page.